Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of Tovecimig on other drugs

1 evidence topic · 1 source

Preclinical interaction with cytotoxic chemotherapy through tumor vessel normalization

“Anti-VEGF therapy is known to normalize tumor blood vessels, leading to a more efficient delivery of cytotoxic anti-cancer agents into tumor tissues” (opens the source at this quote in a new tab)

“Moreover, because the VEGF-binding part of ABL001 is composed of the same IgG backbone and sequence as bevacizumab, ABL001 may have similar activity and function as bevacizumab in tumor vessels, resulting in a more effective delivery of anti-cancer agents, such as paclitaxel or irinotecan.” (opens the source at this quote in a new tab)

Dedicated clinical drug interaction studies

No evidence found.